Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47930 | 0.88 | SIGMAR1 (0.57) | SIGMAR1CHRNA7HRH3DRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL48026 | 0.87 | SIGMAR1 (0.56) | SIGMAR1CHRNA7HRH3DRD2SLC6A4 | |
| SCHEMBL47965 | 0.79 | SIGMAR1 (0.45) | SIGMAR1CHRNA7DRD2SLC6A4CYP2A6 | |
| SCHEMBL5332205 | 0.78 | DRD2 (0.52) | SIGMAR1CHRNA7HRH3DRD2SLC6A4 | |
| SCHEMBL48281 | 0.75 | CYP2A6 (0.56) | CHRNA7CYP2A6AGXTADRB2ASIC3 | |
| SCHEMBL48175 | 0.75 | AGXT (0.47) | CHRNA7CYP2A6AGXTADRB2ASIC3 | |
| Oxalic Acid SCHEMBL48124 | 0.75 | DRD2 (0.44) | SIGMAR1CHRNA7KDM4EDRD2 | |
| SCHEMBL48125 | 0.75 | FAAH (0.41) | CHRNA7DRD2SLC6A4HRH2HRH1 | |
| SCHEMBL9511765 | 0.73 | AGXT (0.45) | CHRNA7CYP2A6AGXTADRB2ASIC3 | |
| SCHEMBL48619 | 0.73 | SIGMAR1 (0.79) | SIGMAR1HRH3SLC6A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | SIGMAR1 1934/4885CHRNA7 180/4885KDM4E 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.